Role of endothelial dysfunction and insulin resistance in angina pectoris and normal coronary angiogram

Herz

Volumn 30, Issue 1, 2005, Pages 48-54

  Monti, Lucilla Domenica ^a   Piatti, Pier Marco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiac syndrome X; Endothelin 1; Endothelium; Insulin resistance

Indexed keywords

ARGININE; ENDOTHELIN 1; ESTRADIOL; NITRIC OXIDE; PRAVASTATIN; TRIMETAZIDINE;

ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL TONE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENDOTHELIUM LESION; EXERCISE TEST; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROVASCULATURE; PERIPHERAL ISCHEMIA; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; SYNDROME X; THORAX PAIN; VASCULAR ENDOTHELIUM; VASODILATATION; VASOSPASM;

ANIMALS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; MICROVASCULAR ANGINA; MODELS, CARDIOVASCULAR; NITRIC OXIDE;

EID: 17144377818     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-005-2638-0     Document Type: Article

References (59)

1. Anderson J L, Horne B D, Jones H U, et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004;101:185-93.
2. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding and endothelin receptor. Nature 1990;348:730-2.
3. Borjesson M, Albertsson P, Delborg M, et al. Esophageal dysfunction in syndrome X. Am J Cardiol 1998;82:1187-91.
4. Botker HE, Moller N, Ovesen P, et al. Insulin resistance in microvascular angina (syndrome X). Lancet 1993;342:136-40.
5. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease. A study of women with chest pain and normal coronary angiograms. Circulation 2004;109:2518-23.
6. Cannon RO, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation 1992;85:883-92.
7. Cannon RO, Epstein SE. Microvascular angina as cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988;61:1338-43.
8. Cannon RO, Peden DB, Berkebile C, et al. Airway hyperresponsiveness in patients with microvascular angina: evidence of a diffuse disorder of smooth muscle responsiveness. Circulation 1990;82:2011-7.
9. Chauhan A, Mullins PA, Petch MC, et al. Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J 1997;18:60-8.
10. Chen JW, Hsu NW, Wu TC, et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide availability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-82.
11. Cosin-Sales J, Pizzi C, Brown S, et al. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003;41:1468-74.
12. Cox ID, Botker HE, Bagger JP, et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. Am J Cardiol 1999;34:455-60.
13. 3-kinase- and MAP kinase-mediated signaling in human muscle.J Clin Invest 2000;105:311-20.
14. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in human vasculature: majority of the ETA sub-type. Br J Pharmacol 1995;114:1110-6.
15. Davis KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: CASS Registry Study. J Am Coll Cardiol 1995;25:1000-9.
16. Dean JD, Jones CJH, Hutchison SJ, et al. Hyperinsulinaemia and microvascular angina ("syndrome X"). Lancet 1991;337:456-7.
17. Di Luozzo G, Bhargava J, Powell RJ. Vascular smooth muscle cell effect on endothelial endothelin-1 production. J Vasc Surg 2000;31:781-9.
18. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94:130-4.
19. Egashira K, Inou T, Hirooka Y, et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993;328:1659-64.
20. Eriksson BE, Tyni-Lenne R, Svedenhag J, et al. Physical training in syndrome X: physical training counteracts deconditioning and pain in syndrome X. J Am Coll Cardiol 2000;36:1619-25.
21. Fujita H, Yamabe H, Yokoyama M. Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms. J Nucl Cardiol 2000;7:97-102.
22. Gewalting MT, Kojda G.Vasoprotection by nitric oxide: mechanisms and therapeutical potential.Cardiovasc Res 2002;55:250-60.
23. Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation 2001;103:E1-6.
24. Godsland IF, Crook D, Stevenson JC, et al. Insulin resistance syndrome in postmenopausal women with cardiological syndrome X. Br Heart J 1995;74:47-52.
25. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
26. Juan SH, Chen JJ, Chen CH, et al. 17beta-estradiol inhibits cyclic strain-induced endothelin-1 expression within vascular endothelial cells. Am J Physiol Heart Circ Physiol 2004;287:H1254-61.
27. Kaski JC, Elliott PM, Salomone O, et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 1995;74:620-4.
28. Kaski JC. Overview of gender aspects of cardiac syndrome X. Cardiovasc Res 2002;53:620-6.
29. Kayikcioglu M, Payzin S, Yavuzgil O, et al. Benefits of statin treatment in cardiac syndrome X. Eur Heart J 2003;24:1999-2005.
30. Kemp HG. Left ventricular function in patients with anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973;32:375-6.
31. Kingwell BA. Nitric oxide-mediated metabolic regulation during exercise: effetcs of training in health and cardiovascular disease. FASEB J 2000;14:1685-96.
32. Kolasinska-Kloch W, Lesniak W, Kiec-Wilk B, et al. Biochemical parameters of endothelial dysfunction in cardiological syndrome X. Scand J Clin Lab Invest 2002;62:7-14.
33. Komoro I, Kurihara H, Sugiyama T, et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cell. FEBS Lett 1988;238:249-52.
34. Lanza GA, Luscher TF, Pasceri V, et al. Effects of arterial pacing on arterial and coronary sinus endothelin-1 levels in syndrome X. Am J Cardiol 1999;84:1187-91.
35. Lerman A, Burnett JC, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8.
36. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
37. Lerman A, Holmes DR Jr, Bell MR, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in human. Circulation 1995;92:2426-31.
38. Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with angina like chest pain and normal coronary angiographic findings. J Am Coll Cardiol 1995;25:1013-8.
39. Lindsay J, Pichard AD. Acute myocardial infarction with normal coronary arteries. J Am Coll Cardiol 1984;54:902-3.
40. Luscher TF, Yang Z, Tschudi M, et al. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990;66:1088-94.
41. Marroquin OC, Kip KE, Kelley DE, et al., Women's Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in woman: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004;109:714-21.
42. Mohri M, Koianagi M, Egashira K, et al. Angina pectoris caused by microvascular spasm. Lancet 1998;351:1156-69.
43. Newby DE, Flint LL, Fox KAA, et al. Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol 1998;31:1585-90.
44. Palloshi A, Fragasso G, Piatti PM, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol 2004;93:930-5.
45. Pasceri V, Lanza GA, Buffon A, et al. Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. Am J Coll Cardiol 1998;31:62-6.
46. Piatti PM, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients who underwent coronary stenting. Circulation 2003;108:2074-81.
47. Piatti PM, Fragasso G, Monti LD, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. Comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 1999;34:1452-60.
48. Piatti PM, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms. Circulation 2003;107:429-36.
49. Piatti PM, Monti LD, Zavaroni I, et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000;85:2416-20.
50. Rogacka D, Guzik P, Wykretowicz A, et al. Effects of trimetazidine on clinical symptoms and tolerance exercise of patients with syndrome X: a preliminary study. Coron Artery Dis 2000;11:171-7.
51. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004;93:159-64.
52. Steinhauff S, Pehlivanli S, Bakovic-Alt R, et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart trasplantation. Transplantation 2004;77:1859-65.
53. Swan JW, Walton C, Godsland IF, et al. Insulin resistance syndrome as a feature of cardiological syndrome X in non-obese men. Br Heart J 1994;71:41-4.
54. Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system:vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 2003;23:1141-52.
55. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
56. Vanhoutte PM. The endothelium: modulator of vascular smooth muscle tone. N Engl J Med 1988;319:512-3.
57. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1988;97:752-6.
58. Yanagisawa M, Kurihara M, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cell. Nature 1988;332:411-5.
59. Young ME, Leighton B. Evidence for alterated sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 1998;329:73-9.